Evaluating Daily Atorvastatin 40mg Versus Placebo for Preventing Chronic Migraine in Adults 18 to 65

What this Trial Is About

Researchers are evaluating whether taking Atorvastatin 40mg daily can prevent chronic migraine episodes in adults aged 18 to 65. This study aims to confirm earlier findings from smaller trials about Atorvastatins beneficial effect and favorable side effect profile, while also exploring if a lower dose might be even better. Additionally, the study will estimate the overall cost of treatment, including medication, acute attack drugs, and lost work time. Participants are randomly assigned to one of two groups one group receives Atorvastatin 40mg once daily for 84 days, while the other takes a placebo daily for the same period. The study uses a triple-blind design to ensure unbiased results and compares these two parallel groups over the treatment period. During the study, participants will keep headache diaries to track migraine frequency. Researchers will measure the number of migraine days every four weeks, along with the number of responders, adverse events, use of acute medication, and days of sick leave over 12 weeks. Safety and effectiveness will be monitored throughout, with study visits scheduled accordingly. The total participation duration covers the treatment and follow-up periods until the study ends in 2029.

Prophylactic Treatment With Atorvastatin for Chronic Migraine (ChronicStatinMig)